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Background: Nucleic acid aptamers have long demonstrated the capacity to bind viral envelope proteins and to
inhibit the progression of pathogenic virus infections. Here we report on initial efforts to develop and screen DNA
aptamers against recombinant envelope proteins or synthetic peptides and whole inactivated viruses from several
virulent arboviruses including Chikungunya, Crimean-Congo hemorrhagic fever (CCHF), dengue, tickborne
encephalitis and West Nile viruses. We also analyzed sequence data and secondary structures for commonalities
that might reveal consensus binding sites among the various aptamers. Some of the highest affinity and most
specific aptamers in the down-selected libraries were demonstrated to have diagnostic utility in lateral flow
chromatographic assays and in a fluorescent aptamer-magnetic bead sandwich assay. Some of the reported
aptamers may also be able to bind viral envelope proteins in vivo and therefore may have antiviral potential in
passive immunity or prophylactic applications.
Results: Several arbovirus DNA aptamer sequences emerged multiple times in the various down selected aptamer
libraries thereby suggesting some consensus sequences for binding arbovirus envelope proteins. Screening of
aptamers by enzyme-linked aptamer sorbent assay (ELASA) was useful for ranking relative aptamer affinities against
their cognate viral targets. Additional study of the aptamer sequences and secondary structures of top-ranked
anti-arboviral aptamers suggest potential virus binding motifs exist within some of the key aptamers and are
highlighted in the supplemental figures for this article. One sequence segment (ACGGGTCCGGACA) emerged 60
times in the anti-CCHF aptamer library, but nowhere else in the anti-arbovirus library and only a few other times in
a larger library of aptamers known to bind bacteria and rickettsia or other targets. Diagnostic utility of some of the
aptamers for arbovirus detection in lateral flow chromatographic assays and a fluorescent sandwich assay on the
surface of magnetic microbeads is also demonstrated.
Conclusions: This article catalogues numerous DNA aptamer sequences which can bind various important
pathogenic arboviruses and have, in some cases, already demonstrated diagnostic potential. These aptamer
sequences are proprietary, patent-pending, and partially characterized. Therefore, they are offered to the scientific
community for potential research use in diagnostic assays, biosensor applications or for possible passive immunity
and prophylaxis against pathogenic viruses.
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The self-professed aim of BMC Research Notes is to “re-
duce the loss suffered by the research community when
results remain unpublished because they do not form a suf-
ficiently complete story to justify the publication of a full re-
search article.” Such is the case with the following body of
aptamer sequence, screening, and structural data for apta-
mers developed against recombinant proteins or synthetic
peptides and whole inactivated viruses that were developed
as part of several Small Business Innovative Research
(SBIR) contracts with the U.S. Defense Department (see the
Acknowledgments section for contract numbers) for diag-
nostic applications. We have assembled a large body of
arboviral aptamer sequence data that has demonstrated ini-
tial diagnostic utility, but also has the potential to serve nu-
merous other diagnostic and therapeutic applications
beyond that which our small group can currently manage.
The aptamer DNA sequences have been divulged in a
U.S. patent application (No. 13/199,082, Publication No.
2012/0149889 A1). While some of the sequences de-
monstrated diagnostic potential in our enzyme-linked
aptamer sorbent assay (ELASA [1,2]), we hypothesize
that the highest affinity and most specific aptamers in
the screened libraries may also have therapeutic, prophy-
lactic, or further diagnostic potential since aptamers
have demonstrated antiviral potential in humans and
animals against influenza [3-5] and a number of other
viruses [6,7] beginning with HIV in the earliest days of
aptamer research [8]. Aptamers may represent a valuable
“bridge to life” if used for passive immunity much like
intravenous antisera for rapidly acting venoms that kill
hosts before an immune response can be induced by a
vaccine. Passive aptamer therapy would also hold the ad-
vantage of low to nonexistent immunogenicity, because
nucleic acids are generally nonimmunogenic and do not
lead to allergic reactions or serum sickness upon subse-
quent administration [9,10].
Arboviruses represent a loosely defined group of
mostly RNA viruses from several different families in-
cluding Bunyaviridae, Flaviviridae, and Togaviridae that
share the characteristic of being transmitted to humans
or other hosts by arthropods. Around the world, some
arboviruses transmitted by mosquitoes, ticks and other
arthropods represent a significant threat to human
health by induction of potentially epidemic encephalitis
or hemorrhagic fevers and other possibly lethal syn-
dromes (e.g., dengue shock syndrome). It is estimated
that there are up to 100 million cases of dengue fever
worldwide each year and of these cases 250,000 are cases
of dengue hemorrhagic fever with 10% mortality [11].
Similarly, Chikungunya virus (CHIKV) infected one-
third of the inhabitants of islands in the Indian ocean
and at least 1 million people on mainland India between
2005–2006 [11-13]. Crimean-Congo Hemorrhagic Fever(CCHF) virus is a lesser known, but highly lethal Nairo-
virus and a member of the Bunyaviridae family which is
transmitted by Hyalomma and other genera of ticks and
has a broad geographic distribution across the Eurasian
and African continents [14-16]. Tickborne encephalitis
virus (TBEV), subtypes European or Western tick-borne
encephalitis virus, Siberian tick-borne encephalitis virus,
and Far-Eastern tick-borne encephalitis virus (formerly
known as Russian spring summer encephalitis virus), are
additional tick-vectored viruses with serious health
implications [17,18]. Finally, West Nile virus (WNV) has
begun posing a significant threat to the U.S. with hun-
dreds to thousands of cases emerging in America every
year since 1999 [19].
With the exceptions of Yellow Fever virus, Japanese en-
cephalitis virus and TBEV, no effective or licensed vac-
cines exist for most arboviruses [18,20-23]. Even the
effective vaccines have drawbacks and can require long
vaccination times before seroconversion in the recipient,
during which time the recipient may be susceptible to the
viral infection. Therefore, we considered developing apta-
mers for both rapid diagnostics and potential therapy or
prophylaxis for arbovirus infections. As aforementioned,
anti-envelope or anti-nucleocapsid DNA and RNA apta-
mers have demonstrated efficacy in blocking or inhibiting
influenza, hepatitis and other viruses in vitro [3-7]. There
is also a rich literature concerning aptamer development
against HIV surface proteins and reverse transcriptase
over the last two decades [8]. These facts, coupled with
the commercial availability of many arbovirus envelope or
nucleocapsid recombinant proteins and synthetic peptides
derived from amino acid sequence data contained within
public protein databases (e.g., entries in Table 1), made
pursuit of aptamers against these otherwise exotic and
dangerous viral targets quite feasible. Ultimately, our apta-
mer candidates will need to be tested in biosafety level 3
(BSL-3) or BSL-4 level laboratories, but our initial aptamer
development using recombinant envelope proteins and
synthetic peptide or inactivated whole virus targets was
very productive.
Materials and methods
Synthetic peptide, recombinant protein, and whole virus
targets and magnetic bead
Immobilization
Table 1 presents data on the commercial sources for re-
combinant viral envelope proteins or synthetic peptide
amino acid sequences for putative epitopes on envelope
proteins used in aptamer development with correspond-
ing references, if available. Recombinant protein or pep-
tide targets (20 μg of each) were immobilized using
100 μl of stock Dynal M280 (2.8 μm diameter; Invitrogen
Corp., Carlsbad, CA) tosyl-coated magnetic beads (MBs)
for 2 hr at 37°C with gentle mixing according to the
Table 1 Viral protein and peptide targets used for anti-arbovirus DNA aptamer development
Virus protein
or peptide






GenScript, Inc. (Piscataway, NJ): GDIQSRTPES KDVYANTQLVLQRPAVGTVHVPYSQAPSGF
KYWLKERGAS; Santhosh et al. [13] and Pubmed Protein Sequence Database
CCHF Altamura
Gn 611
1,641 daltons GenScript; TQEGRGHVKLSRGSE Altamura et al., 2007 [16]
CCHF 11E7a 3,391 daltons GenScript; GLKFASLTCTGCYACSSGISCKVRIHVDEPDE Ahmed, et al., 2005 and
Altamura et al. 2007 [15,16]
CCHF 11E7b 4,482 daltons GenScript; VAASSSLMARKLEFGTDSTFKAFSAMPKTSLCFYIVEREY Ahmed, et al., 2005 and
Altamura et al. 2007 [15,16]
CCHF 11E7c 3,152 daltons Genscript; EDTQKCVNTKLEQPQSILIEHKGTIIGK Ahmed, et al., 2005 and
Altamura et al. 2007 [15,16]
Recombinant
dengue Type 1
41 kD E (envelope)
antigen
Virostat, Inc. (Portland, ME) Product No. 8812
Recombinant
dengue Type 2
15 kD E antigen Virostat; Product No. 8813
Recombinant
dengue Type 3
15 kD E antigen Virostat; Product No. 8814
Recombinant
dengue Type 4
15 kD E antigen Virostat; Product No. 8815
TBEV CE/gE Feldan Bio Corp. (Quebec, Canada) Cat. No. FB03-80-149
WNV E Protein ~ 42 kD E protein GenWay Biotech (San Diego, CA) Cat. No. 10-511-248224
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using a Dynal MPC-S magnetic rack and washed in 1 ml
of 1X binding buffer (1XBB; 0.5 M NaCl, 10 mM Tris–
HCl, and 1 mM MgCl2, pH 7.5-7.6) three times before
storage at 4°C.
In addition to the targets listed in Table 1, some CCHF
aptamer development utilized formalin-fixed whole virus
particles consisting of the IbAr 10200 and Drosdov (Dros)
strains of CCHF (U.S. Army Medical Research Institute
for Infectious Disease; USAMRIID; Ft. Detrick, MD). All
CCHF virus samples were certified as inactive by USAM-
RIID after negative plaque assay results using mammalian
(CER or Vero) cells and an apparent lack of infectivity
based on immunofluorescence microscopy. Inactivated
virus (100 μl) was covalently attached to 100 μl of stock
tosyl-M280 Dynal MBs for 2 hr at 37°C, followed by wa-
shing and storage at 4°C in 1XBB. Protein, peptide, or
whole virus-coated MBs (hereafter referred to as target-
MBs) were used for DNA aptamer development according
to the MB-SELEX procedures previously published by
Bruno et al. [1,2] and briefly summarized below.
Aptamer development, cloning and sequencing
All DNA oligonucleotides were purchased from Inte-
grated DNA Technologies, Inc. (Coralville, IA). MB-
based SELEX (Systematic Evolution of Ligands by Expo-
nential enrichment) was performed using 150 nanomoles
of the degenerate SELEX template library sequence: 50-
ATCCGTCACACCTGCTCT-N36-TGGTGTTGGCTC
CCGTAT-30, where N36 represents the randomized
36-base region of the DNA library. Primer sequenceswere: 50-ATACGGGAGCCAACACCA-30 (designated
forward or F) and 50-ATCCGTCACACCTGCTCT-30
(designated reverse or R) to prime the template and
nascent strands, respectively. The random library was
reconstituted in 500 μl of sterile nuclease-free water
and heated to 95°C for 5 min to ensure that the DNA
library was completely single-stranded (ss) and linear.
The hot template solution was added to 100 μl of
target-MBs (~ 2 X 107 beads) and 600 μl of sterile 2X
Binding Buffer (2XBB) and mixed at room temperature
(RT; ~ 25°C) for 1 hr.
Following interaction with the randomized DNA libra-
ries, DNA-target-MB complexes were separated from un-
bound DNA by magnetic collection and the supernate
was discarded. DNA-target-MBs were then washed three
times in 400 μl of sterile 1XBB with magnetic collection.
DNA-target-MBs (~ 75 μl) were added to separate PCR
reactions to amplify the bound DNA as follows. The MB
pellet was split into 15 μl aliquots and added to five Easy
Start™ Micro 50 PCR tubes (Molecular BioProducts, Inc.,
San Diego, CA), which contained most of the nonperish-
able components of a PCR reaction beneath a wax seal. A
total of 3 μl of 1:10 primer mix (10% forward primer plus
10% reverse primer) in nuclease-free deionized water or ~
20 nanomoles of each primer per ml plus 1 μl (5 U) of
Taq DNA polymerase (Fisher Scientific Inc., Pittsburgh,
PA) were added to each of the five PCR tubes which were
brought to a final volume of 50 μl each with nuclease-free
deionized water. The final MgCl2 concentration was 2
mM. PCR tubes were supplemented with 0.5 μl of Perfect
Match™ E. coli single-strand binding protein (SSBP,
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weight concatamer formation. PCR was carried out as fol-
lows: an initial 95°C phase for 5 min, followed by 30 cycles
of 1 min at 95°C, 1 min at 53°C, and 1 min at 72°C fol-
lowed by a 72°C completion stage for 7 min, and refrige-
ration at 4°C. This constituted the first of 5 to 10 rounds
of MB-SELEX.
CCHF envelope peptides were subjected to 10 rounds
of MB-SELEX while all other targets were subjected to 5
rounds. To begin the second round of MB-SELEX and
all subsequent rounds, 4 complete tubes of the 5 original
PCR tubes were heated to 95°C for 5 min to release
bound DNA target-MBs. The fifth tube was always
retained and refrigerated as a back-up for that round of
the SELEX process. DNA supernate (25 μl per tube) was
siphoned out of the hot tubes without removing the
target-MBs before the tubes cooled significantly and the
DNA was pooled. One hundred μl of hot DNA was
added to 100 μl of fresh target-MBs in 200 μl of 2XBB
and allowed to mix for 1 hr at RT. Thereafter, the selec-
tion and amplification process was repeated for four
more rounds of target-MB SELEX with visual verifica-
tion of 72 bp aptamer PCR products by ethidium
bromide-stained 2% agarose electrophoresis after each
round. Round 5 or 10 aptamers were cloned into che-
mically competent and thawed E. coli using a GC clo-
ning kit (Lucigen Corp., Middleton, WI) according to
the manufacturer’s instructions. Positive clones were
sent to Sequetech Corp. (Mountain View, CA) for pro-
prietary rolling circle amplification (RCA)-based sequen-
cing with betaine, DMSO and high heat treatment using
an ABI 3730 XL automated sequencer. A comprehen-
sive list of all DNA aptamer sequences related to this
work is given in Additional file 1: Table S1. In addition,
these sequences were deposited in the U.S. Patent and
Trademark Office’s database (www.uspto.gov) as part of
U.S. patent application No. 13/199,082.
Enzyme-linked aptamer sorbent assay (ELASA) affinity
screening
One hundred μl of 1:300 diluted stock CCHF IbAr 10200
and Drosdov strain formalin-fixed viruses or 250 ng of tar-
get proteins or peptides were adsorbed in DNAase-free
96-well flat bottom polystyrene microtiter plates (Greiner
Bio-One, GmbH, Frickenhausen, Germany, Product No.
655101) in 100 μl of 0.1M NaHCO3 buffer (pH ~ 8.5) per
well, covered and stored overnight at 4°C. For screening
250 ng of envelope protein or peptide was immobilized
per well. Wells were decanted and washed 3 times in 250
μl of 1XBB for 5 min per wash with gentle mixing and
decanted. Wells were then blocked with 2% ethanolamine
in 0.1M NaHCO3 at 37°C for 1 hr and washed three more
times in 1XBB as before. Plates containing lyophilized 5’-
biotinylated aptamers (4.5 nanomoles per well) fromIntegrated DNA Technologies were rehydrated for 1 hr in
100 μl of 1XBB per well with gentle mixing and trans-
ferred to the microtiter plate according to a pre-defined
map. Aptamers were allowed to interact with targets on
the surface of microtiter wells for 1 hr at RT with gentle
mixing. Wells were then washed three times in 250 μl of
1XBB for 5 min per wash and decanted. One hundred μl
of 1:2,000 streptavidin-peroxidase at 1 mg/ml stock from
Thermo Scientific, Inc. (Pittsburgh, PA; Product No.
21126) in 1XBB was added per well with gentle mixing at
RT for 30 min. Wells were decanted and washed three
more times in 200 μl of 1XBB with gentle mixing for 5
min per wash. Wells were developed by adding 100 μl of
One-Step ABTS (Kirkegaard Perry Labs, Gaithersburg,
MD) which had been pre-warmed to RT) and read after a
15 min development time or until an O.D. (absorbance) at
405 nm of 1.0 to 2.0 was reached at using a Thermo Scien-
tific microplate reader. Averages of two or four replicate
ELASA runs per target are listed in Tables 2, 3 and 4.
Aptamer-based lateral flow (LF) chromatographic assay
development
Aptamers have been successfully used in LF formats by
other researchers [24,25]. We fashioned LF strips from a
combination of a Whatman GB002 sample pad, a What-
man Standard 17 conjugate pad, a Millipore High Flow
240 analytical membrane (for slower 240 second migra-
tion and greatest sensitivity) and a Whatman 470 wick-
ing or absorbent pad all attached on a pressure sensitive
sticky laminate backing (Diagnostic Consulting Network;
DCN, Carlsbad, CA). The sample pad was soaked in
0.05M Tris–HCl (pH 8.03) containing 0.15 mM NaCl
and 0.25% Triton X-100 for 30 min followed by drying
of the sample pad strip at 37°C for several hrs until com-
pletely dry. The components were assembled with the
sample pad overlapping the conjugate pad by ~ 2 mm
and both the conjugate pad and wicking pads were over-
laid on the nitrocellulose analytical membrane at each
end of the analytical membrane. Thereafter, 4 mm wide
strips were cut with a sharp paper cutter and these were
laid into plastic cassettes (DCN) for evaluations.
One hundred μl of 10 O.D. units/ml of colloidal gold-
streptavidin conjugate from DCN was bound to 100 μl
of 5’-biotin-aptamers (ranging from 1.33 to 1.83 mg/ml
with an average molec. wt. of ~ 22.5 kD) which had been
preheated to 95°C for 5 min followed by rapid cooling
at -20°C for 5 min. Each aptamer-biotin-streptavidin-
colloidal gold conjugate was added to 250 μl of 1XBB
buffer and mixed in sterile microfuge tubes for 1 hr at
RT. Fifty μl of 1 μM biotin was added to block any un-
bound streptavidin binding sites and all aptamers were
purified through 30 kD MWCO (molecular weight cut
off) spin columns from PALL Life Sciences (Ann Arbor,
MI) by spinning at 5,000 r.p.m. on an Eppendorf Mini-
Table 2 ELASA affinity rankings for anti-chikungunya (ChE), tick-borne encephalitis virus (TBEV), and west nile virus
(WNV) aptamers
Aptamer Avg. A405 Aptamer Avg. A405 Aptamer Avg. A405
ChE-17R 2.608 TBEV-2R 2.719 WNV-19F 2.607
ChE-20R 2.583 TBEV-2F 2.440 WNV-18R 2.372
ChE-19R 2.582 TBEV-8R 2.428 WNV-16F 2.363
ChE-16F 2.549 TBEV-6R 2.264 WNV-10F 2.349
ChE-19F 2.462 TBEV-6F 2.238 WNV-12R 2.276
ChE-18F 2.428 TBEV-4R 2.210 WNV-20F 2.186
ChE-17F 2.418 TBEV-1R 2.193 WNV-20R 2.043
ChE-20F 2.412 TBEV-5F 2.123 WNV-16R 1.970
ChE-16R 2.411 TBEV-7F 1.929 WNV-3/7/11F 1.816
ChE-18R 2.343 TBEV-7R 1.922 WNV-3/7/11R 1.764
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aptamer conjugate was resuspended in 100 μl of 1XBB off
of the spin column membrane. Capture aptamer-
streptavidin reagents for the test lines (or dots) were made
in precisely the same manner as the reagents for the con-
jugate pads except that the streptavidin was not labeled
with colloidal gold. One μl of the capture aptamer-
streptavidin reagent was spotted onto the analytical mem-
brane at various distances from the conjugate pad, allowed
to air dry and then baked in a UV oven for 15 min (total
imparted energy ~ 0.2 J/cm2). Fifteen μl of each conjugate
aptamer-biotin-streptavidin-colloidal gold reagent were
added to the conjugate pads and air dried for lateral flow
experiments using ~ 1 μg of recombinant envelope pro-
tein or synthetic peptide.
Spectrofluorometric assay and fluorescence microscopic
verification of a CCHF aptamer magnetic bead sandwich
assay
μl of capture aptamer-5’-biotin-streptavidin-magnetic
beads (~ 1.3 X 106 M270 Dynal/Life Technologies, Inc.
MBs per test) that had been washed 3 times in 1 ml of
1XBB on a Dynal MPC-S magnetic collection rack. The
capture aptamer-MB reagents were combined with 20 μlTable 3 ELASA affinity rankings for anti-dengue (DE) serotype
Aptamer Avg. A405 Aptamer Avg. A405
DE1-8R 2.651 DE2 - 2R 1.985
DE1 - 3R 2.552 DE2 - 10F 1.759
DE1-10F 2.455 DE2 - 8R 1.671
DE1-8F 2.404 DE2 - 5Fa 1.641
DE1 -6R 2.321 DE2 - 7F 1.606
DE1-10R 2.124 DE2 - 2F 1.599
DE1 - 4R 2.087 DE2 - 10R 1.572
DE1 - 5Rb 1.906 DE2 - 7R 1.462
DE1 - 9R 1.886 DE2 - 6R 1.451
DE1 - 3F 1.748 DE2 - 9R 1.426(~ 2 μg) of 5’-TYE 665 dye-5’-reporter aptamers (Inte-
grated DNA Technologies, Inc., Ex/Em 645/658-660 nm)
per test. Preliminary testing (not shown) indicated that
these were the optimal reagent amounts to maximize
assay sensitivity. For screening purposes (Figure 1), we
used 150 ng of the inactivated CCHF virus per test (as
determined by a Bradford protein assay) which was per-
formed in triplicate. Titration studies using two-fold serial
dilutions of the inactivated CCHF virus starting with 150
ng of virus per test were conducted in PBS using the most
highly fluorescent combination 20 (Gn6-25R capture
aptamer-MBs plus Gn6-17F-TYE 665 reporter aptamer)
sandwich assay. Fluorescence spectra and emission peak
heights at 658 nm were obtained by collecting all of the
captured virus on aptamer-MBs with a small cylindrical
magnet placed inside a Cary Varian Eclipse spectrofluo-
rometer to hold the MBs in place with 2 ml of PBS in
polystyrene cuvettes. The spectrofluorometer was set to
excite at 645 nm with 5 nm slits and emission spectra
were scanned from 655 to 720 nm using a photomultiplier
tube (PMT) setting of 900 V.
Fluorescence microscopy was performed to verify virus
binding at a total magnification of 400X. Digital images
were taken with an Olympus BH-2 fluorescence1–4 aptamers
Aptamer Avg. A405 Aptamer Avg. A405
DE3 - 1R 1.156 DE4 - 7R 1.910
DE3 - 3Ra 0.782 DE4 - 4R 1.497
DE3 - 4Fa 0.760 DE4 - 4F 1.281
DE3 - 3Rb 0.744 DE4 - 9Fa 1.269
DE3 - 2F 0.732 DE4 - 9Rb 1.241
DE3 - 3Fb 0.730 DE4 - 6R 1.228
DE3 - 3Fa 0.716 DE4 - 5R 1.193
DE3 - 4Rb 0.703 DE4 - 3F 1.178
DE3 - 4Ra 0.682 DE4 - 9Fb 1.171
DE3 - 1F 0.676 DE4 - 7F 1.157
Table 4 ELASA affinity rankings for anti-crimean congo hemorrhagic fever (CCHF) aptamers
Aptamer Avg.A405 Aptamer Avg. A405 Aptamer Avg. A405 Aptamer Avg. A405 Aptamer Avg. A405
Gn6-25R 1.940 E7a-23F 2.230 E7b-1bR 2.069 E7c-23/25R 2.121 Dros-13R 1.267
Gn6-16cF 1.903 E7a-33R 2.123 E7b-8a/10/16-19/23-25R 2.000 E7c-7bF 2.018 Dros-4-7/10R 1.249
Gn6-18F 1.860 E7a-5R 2.084 E7b-1aR 1.999 E7c-27F 2.001 Dros-17R 1.230
Gn6-17F 1.824 E7a-18F 2.082 E7b-3R 1.936 E7c-7aF 1.998 Dros-17F 1.227
Gn6-30F 1.754 E7a-11R 2.073 E7b-14R 1.899 E7c-1bF 1.994 Dros-13F 1.167
Gn6-5F 1.751 E7a-33F 2.070 E7b-1bF 1.875 E7c-4aR 1.988 Dros-16R 1.159
Gn6-7bR 1.688 E7a-29F 2.056 E7b-6R 1.864 E7c-17F 1.982 Dros-16F 1.140
Gn6-16cR 1.668 E7a-20R 2.037 E7b-5R 1.857 E7c-17R 1.958 Dros-4-7/10F 1.136
Gn6-6R 1.639 E7a-8R 2.036 E7b-1aF 1.826 E7c-19F 1.948 Dros-19F 1.103
Gn6-15R 1.633 E7a-20F 2.017 E7b-20/21R 1.781 E7c-24R 1.932 Dros-19R 0.920
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Lake Forest, IL) filter cube customized for use with TYE
665 fluorophore and a Moticam 2000 (2.0 Mega pixel)
digital camera (Motic Instruments, Inc., Richmond, British
Columbia, Canada) and Motic image capture software.
Images were analyzed objectively using NIH Image Java
(Image J) software to generate histograms of red fluores-
cence intensity from the surface of MBs to determine if
fluorescence intensity from the TYE 665 dye was increased
in the presence of 150 ng of inactivated CCHF virus.
Secondary structure determinations
Two dimensional stem-loop structures were generated for
comparison of common loops or potential binding pock-
ets or sites using free internet-based Vienna RNA software
as described by Hofacker [26], except that DNA para-
meters and a temperature setting of 25°C were used. Vi-
enna RNA software is publicly accessible at: http://rna.tbi.
univie.ac.at/cgi-bin/RNAfold.cgi. All secondary structures
are shown in the supplemental figures. While common
loop structures do not necessarily indicate a target bindingFigure 1 Preliminary aptamer LF chromatographic assay experiments
(B) Tick-borne encephalitis virus (TBEV) recombinant envelope protei
strip and ~ 1 μg each target peptide or protein in PBS was used for these
240 analytical membranes were used in each case.site within a family of aptamers, they do represent clearly
accessible single-stranded regions and are probably more
energetically favorable for target binding versus “induced
fit” in double-stranded stem regions wherein the aptamer
would have to be opened by breaking hydrogen bonds be-
tween the nitrogen bases.
Results and discussion
Tables 2, 3, 4 rank the top ten aptamers from each virus
group based on ELASA absorbance (average absorbance
from two or four separate ELASA experiments) from
highest to lowest affinity (greatest to lowest absorbance
at 405 nm). It is important to emphasize that some virus
groups had many more candidate aptamer sequences as
revealed in the comprehensive list (Additional file 1:
Table S1). The four different nucleotides are color-coded
to facilitate visually identifying identical or similar
sequences amidst the complexity in Additional file 1:
Table S1. Only the top ten ELASA rankings for each
viral target are given in Tables 2, 3, 4. Background ab-
sorbance at 405 nm was always < 0.4. The constantfor (A) Chikungunya virus envelope peptide detection and
n detection. Capture and conjugate aptamers are shown for each test
tests which were allowed to develop for 5 min at RT. High Flow (HF)
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GCCAACACCA, AGAGCAGGTGTGACGGAT, ATCC
GTCACACCTGCTCT, and TGGTGTTGGCTCCCGT
AT) on the 50 and 30 ends were included in Additional
file 1: Table S1, because primer regions may contribute
to aptamer binding loops or pockets [27] and may pos-
sibly stabilize secondary or tertiary aptamer structures.
However, our investigations primarily focused on the 36-
base region in the middle of each aptamer as it repre-
sented the most probable location for aptamer binding
due to its randomized nature.
In addition to primary nucleotide sequence compari-
sons, aptamer DNA sequences were also analyzed for
common segments or “runs” present in the predicted
single-stranded loop structures based on secondary struc-
tures derived from internet-based Vienna RNA software
[26] using 25°C and physicochemical parameters asso-
ciated with DNA instead of RNA. Additional file 2: Figures
S1–13 present a great diversity of two-dimensional apta-
mer shapes that sometimes converged on common struc-
tural motifs in whole or in part. This observation
underscored the diversity of the starting random library
that resulted in the convergence of structure and sequence
diversity through the affinity selection and enrichment
process known as SELEX. Common sequences residing in
or proximal to natural loop structures may represent bind-
ing sites and are indicated by the boxed, circled, or under-
lined sequences in Additional file 2: Figures S1–13. While
it is true that induced fit of the target into a double-
stranded (ds) stem region of an aptamer is feasible when
the change in free energy makes binding favorable, extant
single-stranded (ss) loop structures having common
sequences are more likely to fold into binding sites in
most cases and should be considered first for detailed
structural analyses.
Primary nucleotide sequence analysis of the top ten
(Table 2) anti-Chikungunya envelope (ChE) aptamers
presented in Additional file 1: Table S1 revealed a shared
sequence of AACCCGCA in aptamer sequences ChE-
17F and ChE-18R. Most of this segment resides in a loop
structure in ChE-18R as seen in Additional file 2: Figure
S1, but most of this same sequence lies in a ds stem re-
gion in ChE-17F. Therefore, if this sequence is part of a
binding site, it may require induced fit or other tertiary
conformational changes to properly bind ChE. Other
than that observation, only one other similar struc-
ture was noted between ChE aptamers 18F and 19F
in Additional file 2: Figure S1 where it is denoted by
boxes around the structures. These structures, albeit odd,
involve both 18-base primer regions and are therefore less
likely to be involved in aptamer binding [27].
It is interesting to note from Additional file 1: Table
S1, that one of the top ten ELASA ranked (Table 2) anti-
WNV aptamer sequences emerges three times (WNV3F/R was identical to clones 7F/R and 11F/R). To appear
in three of 17 clones (34 total F and R aptamers) or
about 17.6% of the population that started with a diver-
sity of ~ 1015 sequences is significant and may represent
a consensus sequence that has the ability to bind a
WNV envelope protein epitope. In addition, two other
sequences in the top ten anti-WNV aptamer list (WNV-
10F and -19F) differed by only one base (T versus C) as
shown in Additional file 1: Table S1 and Additional file 2:
Figure S13. In addition, WNV-10F and -19F were oddly
truncated to 59 bases as compared to the normal 72 base
length. This may be due to the E. coli host cell excising
a segment from the inserted aptamer in a plasmid or
skipping over a GC-rich “knot” during replication or
sequencing.
The anti-dengue envelope (DE) aptamer analysis (Table 3
and Additional file 1: Table S1) was relatively disappoint-
ing by comparison to the CCHF analysis. With the excep-
tion of a few odd structures contained mostly in the
constant primer ends and a few GC-rich loop structures
which are circled or boxed in Additional file 2: Figures
S8–11, there was no noteworthy convergence to a full-
length consensus sequence, sequence segment, or stem-
loop motif. The anti-dengue aptamers were spread over
four different envelope protein serotypes and only 8 or
9 forward and reverse aptamers were sequenced (16–18
total aptamer sequences per DE serotype for a total of
68 aptamers) as shown in the comprehensive list in
Additional file 1: Table S1. Therefore, more aptamer se-
quencing may be required to define anti-dengue aptamer
consensus sequences for each serotype.
Similar to the BE aptamer analysis, relatively few anti-
TBEV aptamer sequences were identified (18 total
sequences in Additional file 1: Table S1). And similarly,
among the top ten anti-TBEV sequences identified by
the ELASA screening (Table 2), there was very little con-
vergence to common sequences, segments, or structural
motifs as shown in Additional file 2: Figure S12.
No clear consensus or common sequence runs
(Additional file 1: Table S1) emerged from analysis of
the top anti-CCHF Altamura Gn611 [16] aptamers listed
in Table 4, but it is noteworthy that Gn6-25R which
ranked first in the ELASA is identical to another top-
ranked anti-CCHF sequence (E7c-23/25R) at the top of
Tables 4 and 5 as well. Oddly, the Altamura Gn611 pep-
tide and 11E7c peptide (derived from a monoclonal anti-
body binding site on CCHF) do not share much amino
acid sequence identity [15,16]. It appears that the longest
homologous segments are two runs of two amino acids
(TQ and KL, bolded and underlined in Table 1).
Outside of three similar loop structures proximal to the
50 ends of the anti-CCHF 11E7a-5R, -8R and -11R aptamers
(boxed in Additional file 2: Figure S3), analysis of the 11E7a
aptamer sequences shown in Additional file 1: Table S1 and
Table 5 Identical anti-CCHF aptamer sequences (without flanking primer sequences)
Aptamer Sequence
E7c - 23/25R ACAGTTAGAGCTTGCCGTATGCCTTTGTTAACATAA
Gn6 - 25R ACAGTTAGAGCTTGCCGTATGCCTTTGTTAACATAA
E7a - 2/6/28/30bR ACTAACCGAATGGCAGTTTCCCCCTTATCCATCTAT
E7c - 1a/18/20R ACTAACCGAATGGCAGTTTCCCCCTTATCCATCTAT
Gn6 - 11R ACTAACCGAATGGCAGTTTCCCCCTTATCCATCTAT
E7a – 15R GGGATAGGGTCTCGTGCTAGATG
E7b - 13/15R GGGATAGGGTCTCGTGCTAGATG
E7a - 8R CGCTGAAGCAAGACATTATCGGGACATTGCCGTGA
E7b - 20/21R CGCTGAAGCAAGACATTATCGGGACATTGCCGTGA
IbAr 10200 – 2-6/8-11/13-23/25R TGACACGCGTACGGGTCCGGACATGTCATAACGGAC
E7a – 3/10/16/19/21/22R TGACACGCGTACGGGTCCGGACATGTCATAACGGAC
E7b – 8a/10/16-19/23-25R TGACACGCGTACGGGTCCGGACATGTCATAACGGAC
Note: The complementary Forward (F) sequences also match, but were not included for brevity.
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gruence. However, analysis of the sequences in Additional
file 1: Table S1, Additional file 2: Figures S4 and 7, uncov-
ered a common ACGGGTCCGGACA sequence (under-
lined and bolded in Table 5). This is the longest contiguous
sequence common among all of the anti-CCHF aptamers
and if the identical clones are counted, this sequence occurs
60 times in the anti-CCHF aptamer library. In many cases,
the sequence can be extended to include TGTC on its 3’
end as well. Because this sequence run was so prevalent, we
scanned our library of greater than 3,000 aptamerFigure 2 Top – capture and reporter aptamer sandwich matrix used t
Bottom – bar graph showing average peak heights at 658 nm (using TYE 6
the range of the three peak heights. Excitation was at 645 nm with 5 nm s
photomultiplier (PMT) setting of 900 V.sequences developed against various bacterial, viral and
clinical protein or small molecule aptamers and found
that this segment is shared with a few anti-Rickettsia anti-
Listeria flagellin and anti-Salmonella aptamers as well as
one aptamer that binds myoglobin, although the latter may
be purely coincidental. The prevalence of this sequence seg-
ment and its emergence in rickettsia and bacterial binding
populations suggests that it may bind a common epitope
involved in attachment or invasion which may have been
evolutionarily conserved across some viruses and bacterial
cells. The ACGGGTCCGGACA or ACGGGTCCGGAo screen for the best fluorescent aptamer-MB combination.
65 fluorophore) for three separate measurements. Error bars represent
lits and emissions were scanned from 655 to 720 nm with a
Figure 3 Schematic of the refined combination 20 CCHF
prototype assay showing the 146 poly-adenine spacer tail with
a terminal 5’-biotin for coupling to streptavidin (SAv)-coated
MBs and the cut sites where the capture and reporter
aptamers were truncated during synthesis to prevent partial
hybridization in the absence of the virus target, thereby
lowering background fluorescence. The secondary structures of
the capture and reporter aptamers were used to determine where
the primer regions could hybridize and were truncated.
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and stem structures in Additional file 2: Figures S4, 6,
and 7 or specifically with top-ranked anti-CCHF apta-
mer sequences 11E7b-1bR, 11E7b-8aR, Drosdov 4/7/
10R (or simply Dros 4R), Dros 13R, and CCHF IbAr
10200 aptamer clones 2-6/8-23/25/26/28/30/31/33/34R.
Other identical sequences from the CCHF aptamer popu-
lation are delineated in Table 5. Unfortunately, due to
computational limitations, our analysis is limited to one
and two-dimensional aptamer structures and ignores the
role of the many possible three-dimensional aptamer-tar-
get interactions. However, the reader should consider such
3-D geometries and docking possibilities in any important
future analyses, if possible, as our group has done for a
few particular cases in the past [28,29].
To demonstrate utility of at least some of the top affinity
ranked arbovirus candidate aptamers, we attempted to use
the aptamers in a lateral flow chromatographic test strip
format [24,25] and a fluorescent sandwich assay format on
the surfaces of MBs as has been accomplished with
antibody-coated MBs for detection of reoviruses [30].
Figure 1A demonstrates that the Chikungunya envelope
aptamers designated 17R (conjugate) and 20R (capture)
could be used in a colloidal gold LF sandwich strip format.
Interestingly, ChE 17R could not be paired with itself for
both the colloidal gold conjugate and capture roles, be-
cause it gave only a faint red spot (Figure 1A), suggesting
that ChE 17R binds a different epitope on the Ch E1a pep-
tide (Table 1) than does the ChE 20R aptamer (i.e., all of
the ChE 17R eptiopes are bound by 17R aptamer and not
available for capture by the 17R aptamer). Figure 1B illus-
trates that TBEV 2F attached to the colloidal gold conju-
gate and paired with TBEV 8R in the capture dot was a
good combination for detection of the TBEV recombinant
envelope protein (Table 1). However, when TBEV 8R is
paired with itself and competes for the same epitope, de-
tection is not possible (Figure 1B). Similarly, when TBEV
2R is used in the conjugate pad and coupled with TBEV
8R for capture, detection of the recombinant protein failed
(Figure 1), perhaps because the TBEV 2R aptamer inter-
feres with capture by 8R on the membrane. Still, the two
successful detection dots in Figure 1 demonstrate the
feasibility of using some aptamers in an LF strip format
for detection of arbovirus envelope proteins.
In another demonstration of diagnostic potential, we
used some of our top affinity ranked and best studied
CCHF aptamers to devise a preliminary fluorescent
aptamer-MB sandwich assay that can be assessed with a
spectrofluorometer and verified by use of a fluorescence
microscope [30]. Figure 2 shows the results of screening
a 5 X 5 capture and reporter sandwich combination
matrix against 150 ng of whole formalin-fixed IbAr
10200 CCHF virus using peak height at 658 nm from
the fluorescence emission spectra of each sandwichcombination. Clearly superior fluorescence detection
arose from combination no. 20 using Gn6-25R for cap-
ture and Gn6-17F-TYE 665 as the reporter aptamer. It is
interesting to note that all of the strongest fluorescent
assay combinations in Figure 2 bottom (i.e., combination
nos. 10, 11, 15, 16, and 20) involved Gn6-25R or Gn6-
17F and E7A-11R (highlighted in the matrix at the top
of Figure 2).
We further refined the CCHF combination 20 assay by
truncating a few bases from the ends as shown in
Figure 3 to decrease partial hybridization of the capture
and reporter aptamers when no target virus is present,
thereby lowering background fluorescence. We also
lengthened the capture aptamer by adding a 146 poly-
adenine tail having a 5’-biotin terminus to connect it to
the streptavidin (SAv)-coated MBs (Figure 3). The
lengthening of the capture aptamer and truncation of
partially hybridizing ends led to marginal improvement
in assay sensitivity (data not shown). When this
Figure 4 Results of the two-fold serial dilution experiment using formalin-fixed IbAr 10200 strain of CCHF. Excitation was at 645 nm with
5 nm slits and emissions were scanned from 655 to 720 nm with a PMT setting of 900 V. The inset shows fluorescence microscopic images
captured from the zero control (− CCHF virus) and the 150 ng of inactivated virus (+ CCHF virus) samples scraped from the inside of cuvettes
and placed on microscope slides. NIH Image J image analysis software was used to verify that the red TYE 665 fluorescence intensity increased
after capture of 150 ng of CCHF virus as illustrated by the histograms in the inset (highlighted by the arrow).
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fold serial dilutions of formalin-fixed IbAr 10200 CCHF
virus using a spectrofluorometer with a magnet in the
light path behind the collected assay MBs, it performed
well as shown in Figure 4 (inset). Also illustrated in
Figure 4 is the fluorescence microscopy of MBs scraped
from the inside of the cuvettes from the zero added virus
(-CCHF virus) background control versus the + CCHF
virus sample which received 150 ng of the inactivated
virus and yielded clearly stronger red fluorescence which
is visible in the photomicrographs and shows a secondary
peak of stronger fluorescence in the NIH Image J-derived
histogram (arrow in Figure 4 inset).
Conclusions
This article presents a potentially valuable catalogue of
anti-arbovirus DNA aptamer sequences that may some-
day aid in diagnostic assays or devices for rapid and sen-
sitive detection of their cognate arbovirus epitopes. In
addition, the various families of aptamers may find value
for passive immunity or prophylaxis in much the same
way that antisera are used to bind and counteract toxins,
but without the threat of generating an immuneresponse against the aptamers which are thought to be
nonimmunogenic [9,10]. Aptamers should also be less
expensive to produce than humanized monoclonal anti-
bodies, especially if their mass production is eventually
conducted by PCR or other biological processes instead
of parallel chemical synthesis.
Some common full-length or partial sequences were
identified for some of the aptamer families and suggest that
these sequences are best suited to binding viral envelope
proteins. One partial sequence or segment in particular
(ACGGGTCCGGACA) emerged in 60 of the anti-CCHF
aptamers and bound both viral envelope peptides and
whole fixed CCHF viruses, thereby strongly suggesting that
this aptamer region may bind to an exposed epitope. That
same sequence was often, but not always, associated with
an extension of TGTC on its 3’ end. The ACGGGTCCG
GACA sequence is not common in the overall library of
greater than 3,000 candidate aptamer DNA sequences that
our group has amassed over the last ten years, but it can
also be found in a few aptamers that bind species of patho-
genic bacteria and rickettsia as well as the protein myoglo-
bin. The significance of this finding is ambiguous, but
worth reporting for posterity so that future correlations
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potential interest such as AACCCGCA emerged in two
anti-Chikungunya aptamers. Some of these common se-
quence segments exist in or near secondary loop structures
and may represent complete or partial binding sites. In
most cases, common sequences or sequence segments
ranked in the top ten aptamers following ELASA screening,
thereby further solidifying the hypothesis that these
sequences could represent binding sites for viral envelope
or spike proteins. This hypothesis was further verified when
one aptamer was shown to interfere with the binding of a
second aptamer in the LF assay prototypes (e.g., Figure 2b,
TBEV 2R and 8R aptamers).
Clearly more sequencing, ELASA and other screening
methods are needed to clarify some of the questions that
have been raised and superficially addressed herein.
However, we felt that the already large body of sequence,
screening, and structural data warranted release to the
scientific community so that other researchers might
analyze and build from it as well. Finally, the present
work clearly demonstrates diagnostic potential for some
of the candidate arbovirus aptamers in LF assay and
fluorescent MB sandwich assay formats. We are con-
tinuing to use the aptamers reported here in various
assay formats for arbovirus detection and hope to use
the highest affinity aptamers for in vitro (plaque inhi-
bition) and in vivo (animal survival) virus challenge stu-
dies in the future.Additional files
Additional file 1: Comprehensive anti-arbovirus aptamer sequence
list.
Additional file 2: Figure S1. Secondary structures of the top ten ELASA
ranked Chikungunya aptamers. Figure S2. Secondary structures of the
top ten ELASA ranked Crimean-Congo Hemorrhagic Fever (CCHF)
Altamura Gn611 aptamers. Figure S3. Secondary structures of the top
ten ELASA ranked CCHF 11E7a aptamers. Figure S4. Secondary structures
of the top ten ELASA ranked CCHF 11E7b aptamers. Figure S5.
Secondary structures of the top ten ELASA ranked CCHF 11E7c aptamers.
Figure S6. Secondary structures of the top ten ELASA ranked CCHF
Drosdov strain whole virus-developed aptamers. Figure S7. Secondary
structures of consensus CCHF IbAr 10200 strain whole virus-developed
aptamers in the entire aptamer library. Note that the reverse sequence
contains the most common ACGGGTCCGGACA sequence segment
(underlined) in its structure as well. Figure S8. Secondary structures of
the top ten ELASA ranked dengue serotype 1 aptamers. Figure S9.
Secondary structures of the top ten ELASA ranked dengue serotype 2
aptamers. Figure S10. Secondary structures of the top ten ELASA ranked
dengue serotype 3 aptamers. Figure S11. Secondary structures of the
top ten ELASA ranked dengue serotype 4 aptamers. Figure S12.
Secondary structures of the top ten ELASA ranked Tick-borne Encephalitis
Virus (TBEV) aptamers. Figure S13. Secondary structures of the top ten
ELASA ranked West Nile Virus (WNV) aptamers.
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